BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND STAT5B, STAT5, 6777, ENSG00000173757, P51692
30 results:

  • 1.
    Qiao L; Zhang L; Wang H
    Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107702
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. CD25
    Chen Z; Tong L; Neo SY; Li S; Gao J; Schlisio S; Lundqvist A
    Oncoimmunology; 2023; 12(1):2175517. PubMed ID: 36970070
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective.
    Khan M; Ai M; Du K; Song J; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Zhang J; Tian Y; Yuan Y
    Front Immunol; 2022; 13():1062225. PubMed ID: 36605187
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Machine Learning-based Virtual Screening for STAT3 Anticancer Drug Target.
    Wadood A; Ajmal A; Junaid M; Rehman AU; Uddin R; Azam SS; Khan AZ; Ali A
    Curr Pharm Des; 2022; 28(36):3023-3032. PubMed ID: 35909285
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. GZ17-6.02 and axitinib interact to kill renal carcinoma cells.
    Booth L; West C; Moore RP; Hoff DV; Dent P
    Oncotarget; 2022; 13():281-290. PubMed ID: 35136485
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.
    Wang Q; Hu J; Kang W; Wang J; Xiang Y; Fu M; Gao H; Huang Z
    Medicine (Baltimore); 2021 Mar; 100(11):e24949. PubMed ID: 33725966
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Mining therapeutic and prognostic significance of STATs in renal cell carcinoma with bioinformatics analysis.
    Zhou L; Li Y; Li Z; Huang Q
    Genomics; 2020 Nov; 112(6):4100-4114. PubMed ID: 32640276
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Identification of an AP1-ZFP36 Regulatory Network Associated with Breast Cancer Prognosis.
    Canzoneri R; Naipauer J; Stedile M; Rodriguez Peña A; Lacunza E; Gandini NA; Curino AC; Facchinetti MM; Coso OA; Kordon E; Abba MC
    J Mammary Gland Biol Neoplasia; 2020 Jun; 25(2):163-172. PubMed ID: 32248342
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.
    Held MA; Greenfest-Allen E; Su S; Stoeckert CJ; Stokes MP; Wojchowski DM
    Cell Signal; 2020 May; 69():109554. PubMed ID: 32027948
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Dihydrotestosterone promotes kidney cancer cell proliferation by activating the stat5 pathway via androgen and glucocorticoid receptors.
    Pak S; Kim W; Kim Y; Song C; Ahn H
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2293-2301. PubMed ID: 31401673
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Twins with different personalities: stat5b-but not stat5A-has a key role in BCR/ABL-induced leukemia.
    Kollmann S; Grundschober E; Maurer B; Warsch W; Grausenburger R; Edlinger L; Huuhtanen J; Lagger S; Hennighausen L; Valent P; Decker T; Strobl B; Mueller M; Mustjoki S; Hoelbl-Kovacic A; Sexl V
    Leukemia; 2019 Jul; 33(7):1583-1597. PubMed ID: 30679796
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. mTOR masters monocyte development in bone marrow by decreasing the inhibition of stat5 on IRF8.
    Zhao Y; Shen X; Na N; Chu Z; Su H; Chao S; Shi L; Xu Y; Zhang L; Shi B; Zhao Y
    Blood; 2018 Apr; 131(14):1587-1599. PubMed ID: 29463562
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.
    Tao T; Yang X; Zheng J; Feng D; Qin Q; Shi X; Wang Q; Zhao C; Peng Z; Liu H; Jiang WG; He J
    Oncogene; 2017 Nov; 36(44):6119-6131. PubMed ID: 28692056
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Resveratrol attenuates constitutive STAT3 and stat5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
    Kim C; Baek SH; Um JY; Shim BS; Ahn KS
    BMC Nephrol; 2016 Feb; 17():19. PubMed ID: 26911335
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.
    Cai C; Xu YF; Wu ZJ; Dong Q; Li MY; Olson JC; Rabinowitz YM; Wang LH; Sun Y
    World J Urol; 2016 Apr; 34(4):561-7. PubMed ID: 26253654
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
    Monk P; Lam E; Mortazavi A; Kendra K; Lesinski GB; Mace TA; Geyer S; Carson WE; Tahiri S; Bhinder A; Clinton SK; Olencki T
    J Immunother; 2014 Apr; 37(3):180-6. PubMed ID: 24598448
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study.
    Gadd S; Beezhold P; Jennings L; George D; Leuer K; Huang CC; Huff V; Tognon C; Sorensen PH; Triche T; Coffin CM; Perlman EJ
    J Pathol; 2012 Sep; 228(1):119-30. PubMed ID: 22374738
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Interleukin-15 plays a central role in human kidney physiology and cancer through the γc signaling pathway.
    Giron-Michel J; Azzi S; Khawam K; Mortier E; Caignard A; Devocelle A; Ferrini S; Croce M; François H; Lecru L; Charpentier B; Chouaib S; Azzarone B; Eid P
    PLoS One; 2012; 7(2):e31624. PubMed ID: 22363690
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. JAK3 in clear cell renal cell carcinoma: mutational screening and clinical implications.
    de Martino M; Gigante M; Cormio L; Prattichizzo C; Cavalcanti E; Gigante M; Ariano V; Netti GS; Montemurno E; Mancini V; Battaglia M; Gesualdo L; Carrieri G; Ranieri E
    Urol Oncol; 2013 Aug; 31(6):930-7. PubMed ID: 21868263
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
    Botteman MF; Meijboom M; Foley I; Stephens JM; Chen YM; Kaura S
    Eur J Health Econ; 2011 Dec; 12(6):575-88. PubMed ID: 20809091
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.